Iovance reports durable Phase 2 results for frontline melanoma therapy
Iovance Biotherapeutics reported final Phase 2 results for one-time lifileucel plus pembrolizumab in frontline advanced melanoma at the ESMO Congress on October 23, 2026. The regimen produced a 62.5% confirmed objective response rate and a 29.2% complete response rate among 24 patients, while median overall survival was not reached after 50.9 months of median follow-up. Iovance is continuing the randomized Phase 3 TILVANCE-301 trial to evaluate the combination against pembrolizumab alone.
Why it matters
The data support Iovance's effort to expand lifileucel into first-line melanoma treatment, although the combination remains in Phase 3 testing. Iovance says TILVANCE-301 is intended to support a potential approval in frontline advanced melanoma.
Key facts
- 1The final Phase 2 analysis showed a 62.5% confirmed objective response rate and a 29.2% complete response rate. quiverquant.com
- 2Median overall survival was not reached after 50.9 months of median study follow-up. quiverquant.com
- 3Median progression-free survival was 19.8 months. quiverquant.com
- 4The TILVANCE-301 Phase 3 trial is enrolling at more than 80 sites across the U.S., Canada, Europe, and Asia-Pacific. quiverquant.com
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.